CNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centene (CNC) is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 available. The stock is in a clear bullish trend, sentiment is improving, analyst targets remain mostly above the current price, and recent news plus congressional buying support the long case. With the stock still trading below several recent price targets and showing continued recovery momentum, I would buy it now rather than wait for a better entry.
CNC is showing a constructive uptrend. MACD histogram is positive and expanding, signaling strengthening momentum. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which confirms trend alignment across short-, medium-, and long-term periods. RSI_6 at about 70 indicates the stock is near overbought levels, but not a clear reversal signal based on the provided data. Price at 67.81 is just below resistance at 68.169 (R1), with the next upside levels at 70.276 and above. Support sits at 64.76, so the chart suggests the stock is holding a healthy trend near breakout territory.
Congress trading data is mildly positive, with 1 recent purchase and no sales, suggesting some influential buying interest. The broader MCO sector is also benefiting from improving Medicaid margin recovery and stabilizing medical cost trends.
RBC’s initiation at Sector Perform with a $70 target suggests the stock may now be fairly valued after a strong run. Morgan Stanley remains only Equal Weight with a much lower $57 target, showing some disagreement on upside. RSI is elevated, so near-term upside may be less explosive after the strong year-to-date rally. Hedge funds and insiders are neutral, so there is no strong ownership-based confirmation from those groups.
Financial snapshot data was unavailable due to an error, so the latest quarter revenue and earnings figures cannot be directly reviewed here. However, analyst commentary points to recovery in Medicaid margins, favorable Q1 medical cost trends, and improving guidance bias. That suggests the latest quarter season was strong enough to shift Street expectations upward, especially for government business margin recovery and risk-adjustment-related earnings support.
Analyst sentiment has turned constructive over the past month. Several firms raised price targets, including BofA to $74, Barclays to $75, Truist to $71, and Morgan Stanley to $57, while Deutsche Bank upgraded the stock to Buy with an $80 target. RBC recently initiated at Sector Perform with a $70 target, which is a more cautious note and implies limited upside after the rally. Overall, Wall Street is mostly bullish on Centene, but the upside debate is now more about valuation discipline than recovery thesis. The pros view: margin recovery, improving cost trends, and upside to EPS estimates. The cons view: much of the good news may already be priced in after the sharp move higher.
